Preview data. Live ingestion rolls out progressively. Numbers shown are representative seed fixtures until this page reads from the ingestion pipeline.
Mindshare
Modality Mindshare
Which therapeutic modalities are trending up — across science, business, and media.
Share of voice · last 7 days
Modality Mindshare
Source: Clinical trial registries, PubMed, press releases, financial filings · biotech.today analysis
Top Gainers
NameCurrentΔ1DΔ7D
- Molecular glue8.40%▲112.0bps▲224.0bps
- PROTAC19.80%▲78.0bps▲181.0bps
- Radiopharma6.80%▲64.0bps▲150.0bps
- Gene therapy11.20%▲41.0bps▲77.0bps
Top Losers
NameCurrentΔ1DΔ7D
- Peptide3.30%▼78.0bps▼54.0bps
- mRNA13.90%▼44.0bps▼23.0bps
- Small molecule6.10%▼31.0bps▼16.0bps
- Antibody4.50%▼14.0bps▼6.0bps
Leaderboard
1
PROTAC
Targeted protein degraders
88.9
+18.1%
2
ADC
Antibody-drug conjugates
82.4
+4.2%
3
mRNA
mRNA therapeutics & vaccines
74.1
-2.3%
4
Gene therapy
AAV / LNP gene delivery
69.6
+7.7%
5
Cell therapy
CAR-T, TIL, iPSC
62.0
+1.2%
6
Molecular glue
Degrader-family, non-PROTAC
51.4
+22.4%
7
Radiopharmaceutical
Targeted radionuclide therapy
47.9
+15.0%
Mindshare by clinical maturity
How modality mindshare composes across the discovery-to-market pipeline. Earlier stages skew to experimental modalities; later stages stabilise on proven ones.
Stage→ Share
PROTACADCmRNAGene therapyCell therapyMolecular glueRadiopharmaSmall moleculeAntibodyPeptide
Academic
22%
18%
14%
12%
10%
8%
8%
Preclinical
24%
18%
13%
11%
9%
8%
7%
Phase 1
23%
18%
14%
12%
10%
8%
6%
Phase 2
26%
16%
13%
11%
10%
9%
6%
Phase 3
24%
20%
16%
11%
9%
7%
6%
Approved
28%
24%
16%
10%
8%
7%
0%20%40%60%80%100%
Source: PubMed discovery-stage tagging, ClinicalTrials.gov status codes, FDA/EMA approvals · biotech.today analysis
Breakdown
By Phase
(6)- Discovery812
- Preclinical1,104
- Phase 1704
- Phase 2471
- Phase 3198
- Approved82
By Indication
(6)- Oncology1,980
- Autoimmune512
- Neurodegeneration341
- Rare disease306
- Cardiometabolic218
- Infectious disease144
By Developer Type
(4)- Biotech (Series A-C)1,218
- Biotech (public)712
- Big pharma488
- Academic / non-profit241